Daniel Egan, MD April 13, 2012
|
|
- Suzan Preston
- 5 years ago
- Views:
Transcription
1 Daniel Egan, MD April 13, 2012
2 Aug 2006 (at age 15): Acute unprovoked DVT in left common femoral vein Factor V Leiden heterozygous Positive lupus inhibitor Lovenox BID 2 weeks later: increased clot burden, so transitioned to UFH warfarin Difficult to maintain therapeutic INR Reportedly taking warfarin 20mg per day May 2007: anticoagulation discontinued Dec 2009: Intermittent left leg swelling. Angiogram revealed a long segment of stenotic left iliac vein, suggestive of May-Thurner syndrome. s/p balloon angioplasty, endovascular stent x 2 Plavix
3 Sep 2010: Established care at UMWC Had been started on fondaparinux 7.5mg daily for symptoms of venous claudication June 2011: Continued symptoms of venous claudication Femoral vein-to-ivc bypass PFTE graft Maintained on fondaparinux and clopidogrel Multiply recurrent graft thromboses Aug 2011: subtherapeutic on 7.5mg fondaparinux Increased fondaparinux to 10mg daily + clopidogrel July 2011: Seizure-type activity, EEG negative Recurrent thromboses in Nov 2011, Jan 2012 while on fondaparinux + clopidogrel s/p catheter-directed thrombolysis & thrombectomy Feb 2012: Admitted for GI bleed secondary to duodenal ulcers Resolved. Anticoagulation quickly resumed. Fondaparinux peak & trough therapeutic on 10mg; also on clopidogrel Prolonged hospitalization for pain, nausea, infection
4 March 2012: New pulmonary embolism Fondaparinux peak & trough sub-therapeutic despite same dose of 10mg Testing: Anti-cardiolipin & anti-b2 glycoprotein negative Repeat lupus inhibitor positive
5 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Miyakis S et al. J Thromb Haemost 2006; 4:295. DVT 55% Pulmonary embolism 25% MI 3-16% Stroke / TIA 30% Pregnancy Loss?%
6 Livedo Reticularis Thrombocytopenia 11-22% 20-40% Epilepsy Migraine Hemolytic Anemia 11-22% 20% 10% Vianna JL, Khamashta; Am J Med 1994;96:3-9 Mchrani T, Petri M; Amsterdam: Elsevier; p Cervera R; Autoimmun Rev 2008; 7:174-8
7 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Miyakis S et al. J Thromb Haemost 2006; 4:295.
8 B2GPI Cardiolipin Prothrombin, Protein C, Protein S, HMW kininogen, annexin, factors Giannakopoulis, Blood 2009; 113: 985. Passam; Pathology 2004; 36:129 Antibodies recognize B2GPI, cardiolipin, or both.
9 drvvt aptt Kaolin clotting time Silica clotting time Taipan venom time Prothrombin time Hanly, CMAJ 2003; 113: 985
10 In prospective In a retrospective analysis 360 Italian analysis 30-40% of patients Infection with and either patients with apl and LA inflammation or acl followed may SLE or collagen over be associated 4 years, there with vascular disease had was transient a 2.5%/year apl thrombosis incidence Love Ann Intern of Med May thrombotic 1;112(9): event. Finazzi G; Curr Rheumatol Rep 2001;3: % 12-44% % 52.9 % 0 1-5% 1-5% General Population SLE In an ICU ANY LAC acl ab2gpi Mchrani T, Petri M. Epidemiology of the antiphospholipid syndrome. In: Asherson RA, editor, Handbook of systemic autoimmune diseases, vol 10. Amsterdam: Elsevier Wenzel. Crit Care Med 2002, 30: 763.
11 Among 7 studies (a mix of case-control and prospective): acl is associated with increased risk for thrombosis The higher the titer, the stronger the association Galli et al, Blood 2003; 101:1827
12 Among 4 studies (a mix of case-control and prospective): LA is consistently associated with increased risk for thrombosis In a retrospective cohort study of 198 patients with apl, while LA was associated with thrombosis, combined presence of B2-GPI and LA carried a stronger risk. Galli et al, Blood 2003; 101:1827 de Laat HB, Blood 2004;104:
13 Proposed mechanisms include: Activation of platelets Activation of endothelium and monocytes Increased expression of Tissue Factor and cytokines Increased expression of adhesion molecules Activation of the complement pathway Binding to and inhibition of ATIII, Protein C, Protein S, Annexin V Inhibition of B2GPI itself (assuming it has an anticoagulant function)
14 Lim, JAMA 2006; 295: 1050 Treatments In APS patients treated initially for VTE, there was a 52-69% recurrence rate at 5-6 years of follow-up APASS: Nested in two prospective retrospective cohort studies. study within Rosove, Warfarin Ann Intern Aspirin Med Recurrent 1992; 117:303. Stroke Study Khamashta, NEJM (JAMA 1995; 2004; 332: :576) In another No difference prospective in thrombosis study, the or Hazard bleeding Ratio for between recurrence warfarin at 3 months at INR was for & aspirin patients with +apl 325mg Kearon, NEJM 1999; 340:901.
15 Two RCTs have shown high-intensity warfarin (INR ) is not better than moderate-intensity (INR ) in preventing recurrence. Crowther, NEJM 2003; 349:1133. Finazzi, J Thromb Haemost 2005; 3:848. The role of low-molecular weight heparin in patients with refractory APS is limited to case series and case reports Vargas-Hitos et al retrospectively evaluated 23 patients (half with primary APS) for an average of 36 months after switching from warfarin to LMWH and none had any recurrent thrombosis Vargas-Hitos, Ann Rheum Dis 2011; 70:1652 There are no studies evaluating fondaparinux for APS There are no studies evaluating dabigatran or rivaroxiban for APS Catastrophic APS: Observational data of plasma exchange, steroids and anticoagulation
16 The role of antibodies in the pathogenesis of APS is established. Possible strategies: Decrease antibody production Interfering with actions of antibody B cell Targeted therapy: Antibody production Act as antigen presenting cells Other immune functions B effector regulatory cells Cytokine production Hydroxychloroquine: Hematologic effects Cardiovascular benefits Immunomodulation?
17 NZW BXSB F1 mouse model of APS & SLE nephritis: Male offspring produce anti-nuclear antibodies (ANA), including antideoxyribonucleic acid (DNA) autoantibodies and high levels of anti-cardiolipin (acl) antibodies by 12 weeks of age The mice develop clinical manifestations of APS & SLE, such as myocardial infarction, thrombocytopenia, and glomerulonephritis. acl in NZW x BXSB F1 mice require a plasma cofactor such as β2-glycoprotein I (β2gpi) to bind to cardiolipin (CL) and thus possess binding properties similar to the acl in the serum of patients with SLE Gharavi AE, Am J Reprod Immunol 1998, 39:310. Previous studies in NZW BXSB F1 mice demonstrated that T cellinhibitory CTLA4-Ig blocked class switching and prevented the emergence of auto-antibodies, and mice did not develop coronary arterial thromboses or nephropathy Akkerman A, Autoimmunity 2004;37: BAFF: a TNF-like cytokine which supports the survival and differentiation of B cells Acts on the B cell receptors BAFF-R and TACI
18 B cell therapy: animal APS model NZW BXSB F1 mice injected at either 8 or 12 weeks with an adenovirus expressing BAFF-R-Ig: inhibits action of BAFF (decreases B cell activity) BAFF-R-IG resulted in: 1. Less acl in splenic tissue (not shown) 2. No statistically significant difference in serum acl (not shown) 3. Decreased cardiac damage 4. Improved survival Myocardial damage score: 1 - a single area of necrosis, 2 - several areas of necrosis and fibrosis, 3 - extensive focal areas of necrosis and fibrosis, and 4 - full- thickness myocardial infarct Kahn P, Arthritis Rheum 2008; 58:2824
19 Ioannou et al: Within a cohort of 32 patients with refractory SLE treated with rituximab, a retrospective study of 7 patients with > 2 previous positive assays for acl was performed. Rituximab administered as 1g IV x 2 doses two weeks apart Also received chlorpheniramine 4mg PO and methylprednisone 250mg IV A reduction in acl noted in all 7 patients
20 Female Male 7 Kumar et al reviewed all studies of ritixumab in APS published as of August articles documenting 21 patients. No RCTs. Age: 5-69 Median age: Manifestations Others: Seizures, livedo reticularis, papilledema, nephropathy, chorea, fluctuating INR LA acl ab2gpi
21 Details are somewhat limited All 21 received anticoagulation All received rituximab Most: 375 mg/m 2 weekly x4 2 pts: R + CHOP 2 pts: R + Cytoxan All received either PO or IV steroids Some received other immunomodulatory drugs (CsA, hydroxychloroquine, azathioprine) All 5 with CAPS received IVIG or plasmapheresis Reported Improvements
22 Phase II, single-center, open-label trial Not yet published Inclusion Criteria: Age 18 or older + Standard laboratory criteria Any of 6 non-aps criteria manifestations Thrombocytopenia, AIHA, valvular disease, chronic skin ulcers, nephropathy, cognitive dysfunction Intervention: 1g Rituximab x 2 doses + solumedrol Primary outcome: Death, adverse events Secondary outcomes: Clinical improvement for each manifestation Laboratory measures NOT RECURRENT THROMBOTIC EVENTS
23 In vitro and animal studies Rituximab decreased apl levels in patients with SLE Case reports and small case series Some improvements in frequency of thromboses or CAPS reported Many other successes reported are based on other clinical manifestations or lab values An phase II clinical trial of rituximab in primary APS is ongoing but designed to examine safety and improvement in noncriteria manifestations, not thrombotic events
24 Rationale for Hydroxychloroquine (HCQ) in SLE & APS HCQ historically used as DVT prophylaxis in the 1970s and 1980s Multiple studies showed HCQ improved lipid profiles in patients with autoimmune disease In vivo: Inhibits platelet aggregation in vivo Jancinova, Thromb Res 1994; 74: HCQ prevents increased expression of GPIIb/IIIa in platelets exposed to apl Espinola Thromb Haemost 2002; 87: Interferes with antigen processing Lombard-Platlet, Immunology 1993; 80: Decreases binding of apl to phospholipid bilayer Rand, Blood 2008; 112: 1687 Decreases inflammatory cytokines Lombard-Platlet, Immunology 1993; 80:
25 Dose not established in APS In lupus: a dose of 400mg daily or 400mg BID is given for a few weeks until disease response then continued at mg daily for maintenance Side effects: Myopathy Visual changes Use with caution in G6PD-deficiency
26 Ruiz-Irastorza, Lupus 2006, 15: 577. Prospective cohort study of 232 patients with SLE Not selected for apl status Followed for 15 years Primary endpoint: thrombosis 150 patients (64%) received anti-malarials for a median of 52 months 62: Hydroxychloroquine 46: Chloroquine 42: Both In Cox proportional hazards model: Anti-malarials were protective (HR 0.28)
27 Tektonidou, Arthritis Rheum 2009, 61: patients with SLE & apl+ vs 144 apl- age/sex-matched controls Prospectively followed for approximately 9 years Doses of HCQ not reported. There was no significant overall difference in whether HCQ was ever used among +apl patients with or without thrombosis, but a trend towards increased duration of use in those without thrombosis.
28 In multivariate analysis by Cox proportional hazards model: apl+ patients receiving hydroxychloroquine had a 1% lower risk of developing thrombosis per 1 month of treatment (HR per 1 month 0.99) Tektonidou, Arthritis Rheum 2009, 61: 29.
29 A single-center, cross-sectional study compared: 77 apl+ pts with APS (non-pregnant) 56 asymptomatic apl+pts (identified from a SLE registry, or lab database) Examined the last 6 months preceding a thrombotic event versus 6 months prior to last hospital visit for the control group Erkan, Rheumatology 2002: 41: 924.
30 A single-center, cross-sectional study compared: 77 apl+ pts with APS (non-pregnant) 56 asymptomatic apl+pts (identified from a SLE registry, or lab database) Examined the last 6 months preceding a thrombotic event versus 6 months prior to last hospital visit for the control group + Thrombus No thrombus ASA 1/77 18/56 p < HCQ 4/77 21/56 p < Steroids 14/77 25/56 p = IS 9/77 8/56 No dose information provided. Use of HCQ was significantly more frequent in the asymptomatic group. In logistic regression analysis, the probability of an event was reduced by HCQ. Erkan, Rheumatology 2002: 41: 924.
31 In vitro studies Retrospective and prospective studies show a survival benefit and antithrombotic benefit in patients with SLE In patients specifically with apl+: There is a suggestion of benefit in a prospective study In patients with APS: Case reports A cross-sectional study shows a reduced risk for thrombosis with HCQ 13 th International Congess Guidelines on Antiphospholipid Antibodies (Lupus 2011, 20:206): Consider HCQ for recurrent thrombosis (a non-graded recommendation)
32 Transitioned from bivalirudin to dabigatran 150mg BID Hydroxychloroquine 400mg po daily Rituximab 375 mg/m2 IV (2 of 4 doses)
33
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationSindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy
Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306
More informationAll about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
All about Antiphospholipid Syndrome M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India 1 2 3 4 5 6 Antiphospholipid syndrome A study of 192
More informationLupus as a risk factor for cardiovascular disease
Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo
More informationThrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationRituximab. B Cell Inhibition in APS. Methods. B Cell Inhibition in APS. Disclosure 11/6/2011
Rituximab in Antiphospholipid Syndrome (RITAPS) A Pilot Open-Label Phase II Prospective Trial for Non-Criteria Manifestations of Antiphospholipid Antibodies (NCT: 00537290) Disclosure Research Support:
More informationLa sindrome da apl : up to date
La sindrome da apl : up to date PL Meroni Div. of Rheumatology, Dept. Clinical Sciences & Community Health, Univ. of Milan, Ist. G Pini Milan Classification criteria for APS Vascular thrombosis: > 1 episode
More informationAntiphospholipid Syndrome Handbook
Antiphospholipid Syndrome Handbook Maria Laura Bertolaccini, Oier Ateka-Barrutia, and Munther A. Khamashta Antiphospholipid Syndrome Handbook Maria Laura Bertolaccini, MD, PhD Lupus Research Unit The Rayne
More informationLupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid
, Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant
More informationAntiphospholipid antibodies
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Antiphospholipid Antibodies Caron P. Misita, PharmD; Stephan Moll, MD Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationAN INTERESTING CASE OF RESPIRATORY DISTRESS. Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai
AN INTERESTING CASE OF RESPIRATORY DISTRESS Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai 11 month old female infant 1 st born to parents of NC marriage referred from Kolkatta H/O:
More informationAntiphospholipid Syndrome: It s Far More Than You Think
Antiphospholipid Syndrome: It s Far More Than You Think Richard Furie, MD Chief, Division of Rheumatology Northwell Health Professor of Medicine Zucker School of Medicine at Hofstra/Northwell Richard Furie,
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationAnticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationThe Antiphospholipid Syndrome
The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly
More informationKey words: antiphospholipid syndrome, trombosis, pathogenesis
26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-
More informationReview Article Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management An Insight into Future Approaches
Journal of Immunology Research Volume 2015, Article ID 951424, 20 pages http://dx.doi.org/10.1155/2015/951424 Review Article Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current
More informationVascular Protection: Preventing Thrombotic Complications of VTE and PAD
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara
More informationIliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationAnti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome
Coagulation and Transfusion Medicine / PREDICTIVE VALUE OF ANTIPHOSPHOLIPID ANTIBODIES Anti β -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With
More informationCurrent View of the Treatment of Antiphospholipid Syndrome
GROUPE HOSPITALIER PITIE SALPETRIERE Current View of the Treatment of Antiphospholipid Syndrome Pr Zahir AMOURA Department of Internal Medicine French National Reference center for SLE and APS Hôpital
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationPrevalence of antiphospholipid auto antibodies in patients with thrombosis
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 6/ September 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Prevalence of antiphospholipid auto antibodies in patients
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationClinical and immunological characteristics of antiphospholipid syndrome in an Asian population: a retrospective study
Asian Pacific Journal of Allergy and Immunology ORIGINAL ARTICLE Clinical and immunological characteristics of antiphospholipid syndrome in an Asian population: a retrospective study Kanon Jatuworapruk,
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationInteractive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)
Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationVenous interventions in DVT
Venous interventions in DVT Sriram Narayanan Chief of Vascular and Endovascular Surgery, Tan Tock Seng Hospital A/Prof of Surgery, National University of Singapore ANTI-COAGULATION LMWH Warfarin x 6m Acute
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationAPPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up
Supplementary Digital Content 2 Mazodier Lupus Anticoagulant- Hypoprothrombinemia Syndrome: Report of 8 Cases and Review of the Literature Medicine (Baltimore). 2012;91(5). APPEIX 2 Eight New Cases of
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationA Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating Prophylaxis after Deep Vein Thrombosis- Pulmonary Embolism
CASE REPORT http://dx.doi.org/10.4046/trd.2014.77.6.274 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2014;77:274-278 A Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating
More informationPediatric thrombosis: Diagnosis and Management
Pediatric thrombosis: Diagnosis and Management Vilmarie Rodriguez, MD Professor Pediatric and Adolescent Medicine Department of Pediatric and Adolescent Medicine Division Pediatric Hematology-Oncology
More informationAMPLIADO SÍNDROME ANTIFOSFOLÍPIDO SÍNDROME DE SJÖGREN María José Cuadrado Lozano Clínica Universidad de Navarra-Madrid
AMPLIADO SÍNDROME ANTIFOSFOLÍPIDO SÍNDROME DE SJÖGREN María José Cuadrado Lozano Clínica Universidad de Navarra-Madrid PLASMABLAST PROLIFERATION IS ASSOCIATED WITH TLR7 POLYMORPHISMS AND UPREGULATION OF
More informationWarfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time
Clin. Lab. 2009;55:XXX-XXX Copyright ORIGINAL ARTICLE Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time HORATIU OLTEANU 2, KATHARINE. A. DOWNES 1, JIGAR
More informationSinus and Cerebral Vein Thrombosis
Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationMortality in the Catastrophic Antiphospholipid Syndrome
ARTHRITIS & RHEUMATISM Vol. 54, No. 8, August 2006, pp 2568 2576 DOI 10.1002/art.22018 2006, American College of Rheumatology Mortality in the Catastrophic Antiphospholipid Syndrome Causes of Death and
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationLupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome
Turk J Hematol 2007; 24:69-74 Turkish Society of Hematology RESEARCH ARTICLE Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome Shveta Garg, Annamma
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationDISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM
Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationMohammadreza Tabatabaei IBTO COAG LAB
Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants
More informationAcute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial) N Engl J Med. Volume 377(23):2240-2252. December 7, 2017 Wednesday, July 11, 2018, 1:00pm ET Guest
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationAntiphospholipid Syndrome ( APS)
Antiphospholipid Syndrome ( APS) Edward John Walter Bowie, MD Mayo Medical School the first to identify APS as an acquired thrombophilia Graham Robert Vivian Hughes MD FRCP Unit Rayne Institute St Thomas
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationCanadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationSLE and the Antiphospholipid Syndrome
SLE and the Antiphospholipid Syndrome Susan Y. Ritter MD, PhD Associate Physician Division of Rheumatology, Immunology and Allergy Department of Medicine Brigham and Women s Hospital Instructor in Medicine
More informationThe antiphospholipid syndrome: still an enigma
CHALLENGING SCENARIOS IN THROMBOSIS The antiphospholipid syndrome: still an enigma Shruti Chaturvedi 1 and Keith R. McCrae 2 1 Division of Hematology, Vanderbilt University Medical Center, Nashville, TN;
More information